A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Shire has announced plans to acquire dry eye specialist SARcode Bioscience with the aim of expanding its ophthalmics portfolio. Under the terms of the agreement, Shire will pay $160 million upfront and SARcode shareholders will receive additional undisclosed payments upon achievement of certain clinical, regulatory and/or commercial milestones.

FDA's Commissioner discusses pharmacy compounding, EMA updates guidance

Merck's Januvia [sitagliptin] was named 2013 Brand of the Year by Pharmaceutical Executive magazine.

A Massachusetts-based compound pharmacy is voluntarily recalling all sterile compound products dispensed since Jan. 1, 2013 due to possible filament contamination.

AstraZeneca announced further downsizing in response to an expected period of declining revenues in the face of patent expirations. The company will eliminate 2300 positions in sales and general administration.

The New Jersey-licensed specialty pharmacy recalls magnesium sulfate products and halts all production operations.

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Rigaku Raman Technologies announced an updated version of the FirstGuard handheld Raman analyzer at Pittcon 2013.

The 2013 Excipient Information Package (EIP) User Guide is now available for free download from the International Pharmaceutical Excipients Council (IPEC)-Americas.

At Pittcon 2013, Bruker introduced a range of instruments and software updates including two LC-triple quadrupole (LC-TQ) mass spectrometers.

The Excellence Dynamic Mechanical Analyzer DMA 1, introduced by Mettler Toledo offers six different deformation modes to gauge materials performance.

Loss-in-weight feeders provide high accuracy for feeding powders.

Xceleron and JCL Bioassay have entered into a partnership that will offer drug developers access to a range of sensitive and robust analytical platforms for early clinical development across Asia, Europe, and North America.

ThromboGenics' eye drug, Jetrea (ocriplasmin) has been approved in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

AstraZeneca announced that it will consolidate its R&D capabilities into three centers located in Cambridge, UK; Gaithersburg, MD in the US; and M?lndal, Sweden. The reorganization will result in a net loss of 1600 positions, mainly in the UK and the US.

Thermo Fisher Scientific Inc. launched new software, instruments, consumables, and services for analytical applications at Pittcon 2013.

Shimadzu Scientific Instruments introduced several new products at Pittcon 2013.

At Pittcon 2013, Water Corp. announced improvement to chromatography systems and software.

Scientists and instrument manufacturers gather in Philadelphia for Pittcon 2013.

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Collaboration provides pharmaceutical industry customers with access to enzyme expertise and assets resulting in cost-effective, green processing at all phases of development, from preclinical to commercial manufacturing scale.

FDA issues list of 2013 guidance documents.

INTERPOL and 29 of the world’s largest pharmaceutical companies have joined forces in an initiative to battle counterfeit drugs.

America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report.

Product sold online in Malaysia and Indonesia infringes on the company’s trademark.

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

While the number of patent filings at the European Patent Office in 2012 increased by 5.2% over 2011, pharmaceutical-based patents remained flat, and biotechnology patents dropped slightly.